Zealand Pharma A/S (ZLDPF)
Market Cap | 6.19B |
Revenue (ttm) | 8.70M |
Net Income (ttm) | -149.77M |
Shares Out | n/a |
EPS (ttm) | -2.25 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 241 |
Average Volume | 888 |
Open | 86.21 |
Previous Close | 98.91 |
Day's Range | 86.21 - 86.21 |
52-Week Range | 71.20 - 141.74 |
Beta | 0.53 |
RSI | 56.10 |
Earnings Date | Feb 20, 2025 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.
Financial numbers in DKK Financial StatementsNews
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Zealand Pharma's new drug petrelintide will help people lose weight: CEO
Zealand Pharma CEO Adam Steensberg discusses the company's new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.

Roche agrees biggest-ever obesity drug deal
Swiss pharma group signs $5.3bn licensing agreement for next-generation treatment made by Zealand Pharma
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Roche And Zealand Team Up To Develop Petrelintide
Roche partnered with Zealand Pharma to co-develop and co-commercialize petrelintide, a novel amylin analog. Roche gains the most advanced amylin analog that is available and strengthens its obesity pi...

Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche Holdings AG (OTC: RHHBY) confirmed a licensing agreement with Zealand Pharma on Wednesday that will see the two companies co-develop petrelintide . Petrelintide is Zealand Pharma's amylin analo...

New drug candidate will help people lose weight in an easier way, Zealand Pharma CEO says
Zealand Pharma CEO Adam Steensberg discusses the companys new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.

Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
Roche Holding licensed a new weight-loss drug from Zealand Pharma, bolstering the drugmaker’s effort to get into a hot market dominated by Novo Nordisk and Eli Lilly & Co.

Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche takes big step in weight-loss field with $5.3 billion deal.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.
Roche, Zealand Pharma enter $5.3B license deal for obesity treatment

Roche to develop, commercialize obesity drug with Zealand Pharma
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wedn...

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with ...

Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
Basel, 12 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR...
Zealand Pharma targets 15-20% weight loss with petrelintide trials in 2025
Zealand Pharma A/S (ZLDPF) Q4 2024 Earnings Call Transcript

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024
Company announcement – No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format.

Zealand Pharma Announces Financial Results for the Full Year 2024
Company announcement – No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeli...

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Press Release – No. 3 / 2025 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Copenhagen, Denmark, February 13, 2025 – Zealand Pharma A/S (...

Zealand CEO on navigating the obesity space among the two biggest players
CNBC's Angelica Peebles talks to Zealand Pharma CEO Adam Steensberg about how he's differentiating Zealand in the obesity drug race.

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhage...

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
Press Release – No. 2 / 2025 Steven R.

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
Press Release – No. 1 / 2025 Zealand Pharma to present at the 43rd Annual J.P.

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: Z...